Mufaso
@Mufaso7

Currently a Factory/Process Automation Consultant in WNY. Long time ChemE having a career spanning eng/maint and sales roles. Please do your own due diligence.

Joined April 2018
34 Photos and videos
Article

VK2735 -> Week 78: A Model Projection for VANQUISH-1

Introduction $VKTX In prior articles I used a 1st order Bateman function along with known PK to model the amount of #VK2735 compound in the body at any given time over various dosing (titration)

13
15
119
37,656
Article

Viking VK2735 Maintenance Trial- 2 Studies in 1- Why both matter... and what's important

Introduction $VKTX's Maintenance study is technically a 33-week PH1 trial for #VK2735, with 11 small SubQ maintenance arms (n=15 in ten of them, n=30 in one) tested in weeks 22-33. Oral maintenance

12
11
138
85,584
Article

Re-Reading VENTURE Before the Maintenance Readout

Introduction $VKTX It has been a while since we got the results of the Viking Ph2 VENTURE SubQ study for #VK2735. Most remember/cite only the top line WL% data of that study. Importantly, there was a

8
10
117
53,898
Article

Kailera Ribupatide-(a.k.a. Hengrui HRS9531) What the Oral Patent says about this dual GLP1/GIP NME

$KLRA $NVO $LLY $VKTX Introduction Ribupatide (a.k.a. HRS-9531 and KAI-9531) is a once-weekly injectable and oral dual GLP1/GIP receptor agonist developed by Jiangsu Hengrui Pharmaceuticals. It is

3
3
33
22,320
Article

Viking's VK2735 vs Tirzepatide - What the Patent Data Shows About GLP1/GIP Receptor Binding

$VKTX $LLY $NVO Introduction Head-to-head data in Viking's patents compare #VK2735 binding affinity for GLP1 and GIP to that of #Tirzepatide using IC50. Before I share the actual data, I think it is

5
9
53
16,263
Article

New Viking patents confirm VK2735 structure

Methods used to Identify VK2735 from Viking Patents VKTX - I previously posted that NME referred to in the Viking US 2024/0239843 A1 dated Jul 18, 2024 as compound 14 was VK2735 with a 95%

6
14
83
37,828
Article

Amylin combo's are the mainstream future of successful diabesity drugs

$LLY has eloralintide and it looks very promising in combo with Tirzepatide. It will be a several years before it could possibly get approval but if it does get approved it would likely raise the bar
7
749
Article

Unpacking hidden value in the VK2735 Ph1 Maintenance study

The #VK2735 Maintenance Study intent which is find out if a monthly SubQ or Weekly Oral or Daily Oral can serve as an effective Weight Maintenance strategy using a reduce amount of API. This study is

6
6
71
30,759
Article

Upcoming Viking Catalysts

Top line Phase2 ORAL VK2735 data is imminent But beyond that $VKTX has a lot going on. The most significant is the AMYLIN agonist IND which is actually a DACRA (Dual Amylin and Calcitonin Receptor

6
8
64
15,522
Article

Goldman on obesity TAM

$VKTX VK2735 as an SC should hit the market in 2028 and be a mega blockbuster. $LLY could continue to do well but Viking stands to do even better as it has BIC potential in both ORAL and SC settings.
18
1,775
Article

VK2735 Oral Phase 2 -> GI Tolerability likely to be "Best in Class" by a Wide Margin.

$VKTX - GI Tolerability was FANTASTIC for #VK2735 Oral in Phase 1. In Phase 2 tolerability will likely be even better and MAY BE AN ORDER OF MAGNITUDE BETTER than anything seen to date! (Oral or SC)

9
27
118
52,188
Article

Tirzepatide- Main reasons Lilly spent so much building factories (and Viking will spend far less)

Introduction Eli Lilly has made a massive investment in manufacturing facilities to produce tirzepatide. Since 2020, they have committed over $18 billion (including the upcoming $5.3 B for the

16
22
165
114,096
Load more